Glycans and galectins in prostate cancer biology, angiogenesis and metastasis

Glycobiology

Volumn 24, Issue 10, 2014, Pages 899-906

  Compagno, Daniel ^a   Gentilini, Lucas D ^a   Jaworski, Felipe M ^a   Pérez, Ignacio González ^a   Contrufo, Geraldine ^a   Laderach, Diego J ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Angiogenesis and metastasis; Carbohydrate; Galectin; Glycan; Prostate tumor

Indexed keywords

GALECTIN; GALECTIN 1; GALECTIN 3; GALECTIN 8; GLYCAN; GLYCOCONJUGATE; LECTIN; POLYSACCHARIDE;

ANGIOGENESIS; APOPTOSIS; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; GLYCOSYLATION; HUMAN; METASTASIS; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; TUMOR CELL; CELL MOTION; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PROSTATE TUMOR;

APOPTOSIS; CELL MOVEMENT; CELL PROLIFERATION; GALECTINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; POLYSACCHARIDES; PROSTATIC NEOPLASMS;

EID: 84925684910     PISSN: 09596658     EISSN: 14602423     Source Type: Journal    
DOI: 10.1093/glycob/cwu055     Document Type: Review

References (93)

1. Ahmed H, Banerjee PP, Vasta GR. 2007. Differential expression of galectins in normal, benign and malignant prostate epithelial cells: Silencing of Galectin-3 expression in prostate cancer by its promoter methylation. Biochem Biophys Res Commun. 358: 241-246.
2. Balan V, Nangia-Makker P, Kho DH, Wang Y, Raz A. 2012. Tyrosine-phosphorylated Galectin-3 protein is resistant to prostate-specific antigen (Psa) cleavage. J Biol Chem. 287: 5192-5198.
3. Barthel SR, Gavino JD, Wiese GK, Jaynes JM, Siddiqui J, Dimitroff CJ. 2008. Analysis of glycosyltransferase expression in metastatic prostate cancer cells capable of rolling activity on microvascular endothelial (E)-selectin. Glycobiology. 18: 806-817.
4. Brockhausen I. 1999. Pathways of O-glycan biosynthesis in cancer cells. Biochim Biophys Acta. 1473: 67-95.
5. Brooks SA, Hall DM. 2012. Lectin histochemistry to detect altered glycosylation in cells and tissues. Methods Mol Biol. 878: 31-50.
6. Califice S, Castronovo V, Bracke M, van den Brule F. 2004. Dual activities of Galectin-3 in human prostate cancer: Tumor suppression of nuclear Galectin-3 vs tumor promotion of cytoplasmic Galectin-3. Oncogene. 23: 7527-7536.
7. Chauchereau A. 2011. Experimental models for the development of new medical treatments in prostate cancer. Eur J Cancer. 47: S200-S214.
8. Clausse N, van den Brule F, Waltregny D, Garnier F, Castronovo V. 1999. Galectin-1 expression in prostate tumor-associated capillary endothelial cells is increased by prostate carcinoma cells and modulates heterotypic cell-cell adhesion. Angiogenesis. 3: 317-325.
9. Compagno D, Jaworski FM, Gentilini L, Contrufo G, Gonzalez-Perez I, Elola MT, Rabinovich GA, Pregi N, Laderach DJ. 2014. Galectins: Major signaling modulators inside and outside the cell. Curr Mol Med. [Epub ahead of print].
10. Compagno D, Laderach DJ, Gentilini L, Jaworski FM, Rabinovich GA. 2013. Delineating the "galectin signature" of tumor microenvironment. Oncoimmunology. 2: e23565.
11. Compagno D, Merle C, Morin A, Gilbert C, Mathieu J, Bozec A, Mauduit C, Benahmed M, Cabon F. 2007. Sirna-directed in vivo silencing of androgen receptor inhibits the growth of castration-resistant prostate carcinomas. PLoS ONE. 2: e1006.
12. Croci DO, Cerliani JP, Dalotto-Moreno T, Mendez-Huergo SP, Mascanfroni ID, Dergan-Dylon S, Toscano MA, Caramelo JJ, Garcia-Vallejo JJ, Ouyang J, et al. 2014. Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors. Cell. 156: 744-758.
13. Croci DO, Salatino M, Rubinstein N, Cerliani JP, Cavallin LE, Leung HJ, Ouyang J, Ilarregui JM, Toscano MA, Domaica CI, et al. 2012. Disrupting Galectin-1 interactions with N-Glycans suppresses hypoxia-driven angiogenesis and tumorigenesis in Kaposi's Sarcoma. J Exp Med. 209: 1985-2000.
14. Cueni LN, Detmar M. 2009. Galectin-8 interacts with podoplanin and modulates lymphatic endothelial cell functions. Exp Cell Res. 315: 1715-1723.
15. Dalziel M, Crispin M, Scanlan CN, Zitzmann N, Dwek RA. 2014. Emerging principles for the therapeutic exploitation of glycosylation. Science. 343: 1235681.
16. Delgado VM, Nugnes LG, Colombo LL, Troncoso MF, Fernandez MM, Malchiodi EL, Frahm I, Croci DO, Compagno D, Rabinovich GA, et al. 2011. Modulation of endothelial cell migration and angiogenesis: A novel function for the "Tandem-Repeat" lectin Galectin-8. FASEB J. 25: 242-254.
17. Denmeade SR, Isaacs JT 2002. A history of prostate cancer treatment. Nat Rev Cancer. 2: 389-396.
18. D'Haene N, Sauvage S, Maris C, Adanja I, Le Mercier M, Decaestecker C, Baum L, Salmon I. 2013. Vegfr1 and Vegfr2 involvement in extracellular Galectin-1- and Galectin-3-induced angiogenesis. PLoS ONE. 8: e67029.
19. Di Lella S, Sundblad V, Cerliani JP, Guardia CM, Estrin DA, Vasta GR, Rabinovich GA. 2011. When galectins recognize glycans: From biochemistry to physiology and back again. Biochemistry. 50: 7842-7857.
20. Dube DH, Bertozzi CR. 2005. Glycans in cancer and inflammation - potential for therapeutics and diagnostics. Nat Rev Drug Discov. 4: 477-488.
21. Ellerhorst J, Nguyen T, Cooper DN, Lotan D, Lotan R. 1999. Differential expression of endogenous Galectin-1 and Galectin-3 in human prostate cancer cell lines and effects of overexpressing Galectin-1 on cell phenotype. Int J Oncol. 14: 217-224.
22. Ellerhorst J, Troncoso P, Xu XC, Lee J, Lotan R. 1999. Galectin-1 and Galectin-3 expression in human prostate tissue and prostate cancer. Urol Res. 27: 362-367.
23. Fry S, Afrough B, Leathem A, Dwek M. 2012. Lectin array-based strategies for identifying metastasis-associated changes in glycosylation. Methods Mol Biol. 878: 267-272.
24. Fukumori T, Kanayama H-o, Raz A. 2007. The role of Galectin-3 in cancer drug resistance. Drug Resist Updates. 10: 101-108.
25. Fukushima K, Satoh T, Baba S, Yamashita K. 2010. Alpha1,2-fucosylated and beta-N-acetylgalactosaminylated prostate-specific antigen as an efficient marker of prostatic cancer. Glycobiology. 20: 452-460.
26. Geney R, Ungureanu IM, Li D, Ojima I. 2002. Overcoming multidrug resistance in taxane chemotherapy. Clin Chem Lab Med. 40: 918-925.
27. Gilgunn S, Conroy PJ, Saldova R, Rudd PM, O'Kennedy RJ. 2013. Aberrant Psa glycosylation - a sweet predictor of prostate cancer. Nat Rev Urol. 10: 99-107.
28. Gleason DF 1988. Histologic grade, clinical stage, and patient age in prostate cancer. NCIMonogr. 15-18.
29. Glinskii OV, Huxley VH, Glinsky GV, Pienta KJ, Raz A, Glinsky VV. 2005. Mechanical entrapment is insufficient and intercellular adhesion is essential for metastatic cell arrest in distant organs. Neoplasia. 7: 522-527.
30. Glinskii OV Li F, Wilson LS, Barnes S, Rittenhouse-Olson K, Barchi JJ, Jr., Pienta KJ, Glinsky VV. 2014. Endothelial integrin Alpha3beta1 stabilizes carbohydrate-mediated tumor/endothelial cell adhesion and induces macro-molecular signaling complex formation at the endothelial cell membrane. Oncotarget. 5: 1382-1389.
31. Glinskii OV, Sud S, Mossine VV, Mawhinney TP, Anthony DC, Glinsky GV, Pienta KJ, Glinsky VV. 2012. Inhibition of prostate cancer bone metastasis by synthetic Tf antigen Mimic/Galectin-3 inhibitor Lactulose-L-Leucine. Neoplasia. 14: 65-73.
32. Glinsky VV, Glinsky GV, Rittenhouse-Olson K, Huflejt ME, Glinskii OV, Deutscher SL, Quinn TP. 2001. The role of Thomsen-Friedenreich antigen in adhesion of human breast and prostate cancer cells to the endothelium. Cancer Res. 61: 4851-4857.
33. Glinsky VV, Glinsky GV, Glinskii OV, Huxley VH, Turk JR, Mossine VV, Deutscher SL, Pienta KJ, Quinn TP. 2003. Intravascular metastatic cancer cell homotypic aggregation at the sites of primary attachment to the endothelium. Cancer Res. 63: 3805-3811.
34. Glinsky VV, Kiriakova G, Glinskii OV, Mossine VV, Mawhinney TP, Turk JR, Glinskii AB, Huxley VH, Price JE, Glinsky GV. 2009. Synthetic Galectin-3 inhibitor increases metastatic cancer cell sensitivity to taxol-induced apoptosis in vitro and in vivo. Neoplasia. 11: 901-909.
35. Glinsky GV, Mossine VV, Price JE, Bielenberg D, Glinsky VV, Ananthaswamy HN, Feather MS. 1996. Inhibition of colony formation in agarose of metastatic human breast carcinoma and melanoma cells by synthetic glycoamine analogs. Clin Exp Metastasis. 14: 253-267.
36. Grabowska MM, Degraff DJ, Yu X, Jin RJ, Chen Z, Borowsky AD, Matusik RJ. 2014. Mouse models of prostate cancer: Picking the best model for the question. Cancer Metastasis Rev. PMID: 24452759. [Epub ahead of print].
37. Guha P, Kaptan E, Bandyopadhyaya G, Kaczanowska S, Davila E, Thompson K, Martin SS, Kalvakolanu DV, Vasta GR, Ahmed H. 2013. Cod glycopeptide with picomolar affinity to Galectin-3 suppresses T-cell apoptosis and prostate cancer metastasis. Proc Natl Acad Sci USA. 110: 5052-5057.
38. Hadari YR, Arbel-Goren R, Levy Y, Amsterdam A, Alon R, Zakut R, Zick Y. 2000. Galectin-8 binding to integrins inhibits cell adhesion and induces apoptosis. J Cell Sci. 113 (Pt 13): 2385-2397.
39. Hauselmann I, Borsig L. 2014. Altered tumor-cell glycosylation promotes metastasis. Front Oncol. 4: 28.
40. He J, Baum LG. 2006. Endothelial cell expression of Galectin-1 induced by prostate cancer cells inhibits T-cell transendothelial migration. Lab Invest. 86: 578-590.
41. Heimburg J, Yan J, Morey S, Glinskii OV, Huxley VH, Wild L, Klick R, Roy R, Glinsky VV, Rittenhouse-Olson K. 2006. Inhibition of spontaneous breast cancer metastasis by anti-Thomsen-Friedenreich antigen monoclonal antibody Jaa-F11. Neoplasia. 8: 939-948.
42. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. 2011. Global cancer statistics. CA Cancer J Clin. 61: 69-90.
43. Johnson KD, Glinskii OV, Mossine VV, Turk JR, Mawhinney TP, Anthony DC, Henry CJ, Huxley VH, Glinsky GV, Pienta KJ, et al. 2007. Galectin-3 as a potential therapeutic target in tumors arising from malignant endothelia. Neoplasia. 9: 662-670.
44. Kamigaito T, Okaneya T, Kawakubo M, Shimojo H, Nishizawa O, Nakayama J. 2014. Overexpression of O-Glcnac by prostate cancer cells is significantly associated with poor prognosis of patients. Prostate Cancer Prostatic Dis. 17: 18-22.
45. Knapp JS, Lokeshwar SD, Vogel U, Hennenlotter J, Schwentner C, Kramer MW, Stenzl A, Merseburger AS. 2013. Galectin-3 expression in prostate cancer and benign prostate tissues: Correlation with biochemical recurrence. World J Urol. 31: 351-358.
46. Laderach DJ, Compagno D, Toscano MA, Croci DO, Dergan-Dylon S, Salatino M, Rabinovich GA. 2010. Dissecting the signal transduction pathways triggered by galectin-glycan interactions in physiological and pathological settings. IUBMB Life. 62: 1-13.
47. Laderach DJ, Gentilini LD, Giribaldi L, Delgado VC, Nugnes L, Croci DO, Al Nakouzi N, Sacca P, Casas G, Mazza O, et al. 2013. A unique galectin signature in human prostate cancer progression suggests Galectin-1 as a key target for treatment of advanced disease. Cancer Res. 73: 86-96.
48. Lange T, Ullrich S, Muller I, Nentwich MF, Stubke K, Feldhaus S, Knies C, Hellwinkel OJ, Vessella RL, Abramjuk C, et al. 2012. Human prostate cancer in a clinically relevant Xenograft mouse model: Identification of beta(1,6)-branched oligosaccharides as a marker of tumor progression. Clin Cancer Res. 18: 1364-1373.
49. Lee SH, Hatakeyama S, Yu SY, Bao X, Ohyama C, Khoo KH, Fukuda MN, Fukuda M. 2009. Core3 O-glycan synthase suppresses tumor formation and metastasis of prostate carcinoma Pc3 and Lncap cells through down-regulation of Alpha2beta1 integrin complex. J Biol Chem. 284: 17157-17169.
50. Lehr JE, Pienta KJ. 1998. Preferential adhesion of prostate cancer cells to a human bone marrow endothelial cell line. J Natl Cancer Inst. 90: 118-123.
51. Levy Y, Arbel-Goren R, Hadari YR, Eshhar S, Ronen D, Elhanany E, Geiger B, Zick Y 2001. Galectin-8 functions as a matricellular modulator of cell adhesion. J Biol Chem. 276: 31285-31295.
52. Levy Y, Ronen D, Bershadsky AD, Zick Y. 2003. Sustained Induction of Erk, protein kinase B, and P70 S6 kinase regulates cell spreading and formation of F-actin microspikes upon ligation of integrins by Galectin-8, a mammalian lectin. J Biol Chem. 278: 14533-14542.
53. Li J, Guillebon AD, Hsu JW, Barthel SR, Dimitroff CJ, Lee YF, King MR. 2013. Human fucosyltransferase 6 enables prostate cancer metastasis to bone. Br J Cancer. 109: 3014-3022.
54. Liu FT, Rabinovich GA. 2005. Galectins as modulators of tumour progression. Nat Rev Cancer. 5: 29-41.
55. Liu X, Yang P, Hart G. 2014. O-Glcnacylation modifies the metastatic properties of prostate cancer cells. FASEB J. 28: 789-795.
56. Lynch TP, Ferrer CM, Jackson SR, Shahriari KS, Vosseller K, Reginato MJ. 2012. Critical role of O-linked beta-N-acetylglucosamine transferase in prostate cancer invasion, angiogenesis, and metastasis. J Biol Chem. 287: 11070-11081.
57. Mariño K, Bones J, Kattla JJ, Rudd PM. 2010. A systematic approach to protein glycosylation analysis: A path through the maze. Nat Chem Biol. 6: 713-723.
58. Markowska AI, Liu FT, Panjwani N. 2011. Galectin-3 is an important mediator of Vegf- and Bfgf-mediated angiogenic response. J Exp Med. 207: 1981-1993.
59. Mechref Y, Hu Y, Garcia A, Zhou S, Desantos-Garcia JL, Hussein A. 2012. Defining putative glycan cancer biomarkers by Ms. Bioanalysis. 4: 2457-2469.
60. Merseburger AS, Kramer MW, Hennenlotter J, Simon P, Knapp J, Hartmann JT, Stenzl A, Serth J, Kuczyk MA. 2008. Involvement of decreased Galectin-3 expression in the pathogenesis and progression of prostate cancer. Prostate. 68: 72-77.
61. Miller V 2001. Interpretation of resistance assay results. Antivir Ther. 6 (SUPPL. 2): 1-9.
62. Nangia-Makker P, Hogan V, Honjo Y, Baccarini S, Tait L, Bresalier R, Raz A. 2002. Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin. J Natl Cancer Inst. 94: 1854-1862.
63. Nangia-Makker P, Honjo Y, Sarvis R, Akahani S, Hogan V, Pienta KJ, Raz A. 2000. Galectin-3 induces endothelial cell morphogenesis and angiogenesis. Am J Pathol. 156: 899-909.
64. Nangia-Makker P, Wang Y, Raz T, Tait L, Balan V, Hogan V, Raz A. 2010. Cleavage of Galectin-3 by matrix metalloproteases induces angiogenesis in breast cancer. Int J Cancer. 127: 2530-2541.
65. Ohyama C, Hosono M, Nitta K, Oh-eda M, Yoshikawa K, Habuchi T, Arai Y, Fukuda M. 2004. Carbohydrate structure and differential binding of prostate specific antigen to Maackia amurensis lectin between prostate cancer and benign prostate hypertrophy. Glycobiology. 14: 671-679.
66. Okamoto T, Yoneyama MS, Hatakeyama S, Mori K, Yamamoto H, Koie T, Saitoh H, Yamaya K, Funyu T, Fukuda M, et al. 2013. Core2 O-glycan-expressing prostate cancer cells are resistant to Nk cell immunity. Mol Med Rep. 7: 359-364.
67. Packer NH, von der Lieth CW, Aoki-Kinoshita KF, Lebrilla CB, Paulson JC, Raman R, Rudd P, Sasisekharan R, Taniguchi N, York WS. 2008. Frontiers in glycomics: bioinformatics and biomarkers in disease. An Nih white paper prepared from discussions by the focus groups at a workshop on the Nih campus, Bethesda, MD (September 11-13, 2006). Proteomics. 8: 8-20.
68. Peracaula R, Tabares G, Royle L, Harvey DJ, Dwek RA, Rudd PM, de Llorens R. 2003. Altered glycosylation pattern allows the distinction between prostate-specific antigen (Psa) from normal and tumor origins. Glycobiology. 13: 457-470.
69. Petrylak DP 2005. The current role of chemotherapy in metastatic hormone-refractory prostate cancer. Urology. 65: 3-7; discussion 7-8
70. Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jr., Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, et al. 2004. Docetaxel and estra-mustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. NEngl JMed. 351: 1513-1520.
71. Pienta KJ, Loberg R. 2005. The "emigration, migration, and immigration" of prostate cancer. Clin Prostate Cancer. 4: 24-30.
72. Pienta KJ, Naik H, Akhtar A, Yamazaki K, Replogle TS, Lehr J, Donat TL, Tait L, Hogan V, Raz A. 1995. Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin. J Natl Cancer Inst. 87: 348-353.
73. Rabinovich GA, Croci DO. 2012. Regulatory circuits mediated by lectin-glycan interactions in autoimmunity and cancer. Immunity. 36: 322-335.
74. Rabinovich GA, Toscano MA. 2009. Turning "Sweet" on immunity: Galectin-Glycan interactions in immune tolerance and inflammation. Nat Rev Immunol. 9: 338-352.
75. Roodman GD 2004. Mechanisms of bone metastasis. Discov Med. 4: 144-148.
76. Saldova R, Fan Y, Fitzpatrick JM, Watson RW, Rudd PM. 2011. Core fucosylation and Alpha2-3 sialylation in serum N-glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasia. Glycobiology. 21: 195-205.
77. Saraswati S, Block AS, Davidson MK, Rank RG, Mahadevan M, Diekman AB. 2011. Galectin-3 is a substrate for prostate specific antigen (Psa) in human seminal plasma. Prostate. 71: 197-208.
78. Slovin SF, Ragupathi G, Musselli C, Olkiewicz K, Verbel D, Kuduk SD, Schwarz JB, Sames D, Danishefsky S, Livingston PO, et al. 2003. Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: Clinical trial results with alpha-N-acetylgalactosamine-O-serine/threonine conjugate vaccine. J Clin Oncol. 21: 4292-4298.
79. Su ZZ, Lin J, Shen R, Fisher PE, Goldstein NI, Fisher PB. 1996. Surface-epitope masking and expression cloning identifies the human prostate carcinoma tumor antigen gene Pcta-1 a member of the galectin gene family. Proc Natl Acad Sci USA. 93: 7252-7257.
80. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, et al. 2004. Docetaxel plus prednisone or Mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 351: 1502-1512.
81. Thijssen VL, Barkan B, Shoji H, Aries IM, Mathieu V, Deltour L, Hackeng TM, Kiss R, Kloog Y, Poirier F, et al. 2010. Tumor cells secrete Galectin-1 to enhance endothelial cell activity. Cancer Res. 70: 6216-6224.
82. Thijssen VL, Postel R, Brandwijk RJ, Dings RP, Nesmelova I, Satijn S, Verhofstad N, Nakabeppu Y, Baum LG, Bakkers J, et al. 2006. Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc Natl Acad Sci USA. 103: 15975-15980.
83. Valenzuela HF, Pace KE, Cabrera PV, White R, Porvari K, Kaija H, Vihko P, Baum LG. 2007. O-Glycosylation regulates Lncap prostate cancer cell susceptibility to apoptosis induced by Galectin-1. Cancer Res. 67: 6155-6162.
84. van den Brule FA, Waltregny D, Waltregny D, Liu FT, Castronovo V 2000. Alteration of the cytoplasmic/nuclear expression pattern of Galectin-3 correlates with prostate carcinoma progression. Int J Cancer. 89: 361-367.
85. van Kooyk Y, Rabinovich GA. 2008. Protein-glycan interactions in the control of innate and adaptive immune responses. Nat Immunol. 9: 593-601.
86. Wang Y, Balan V, Gao X, Reddy PG, Kho D, Tait L, Raz A. 2013. The significance of Galectin-3 as a New Basal Cell Marker in prostate cancer. Cell Death Dis. 4: e753.
87. Wang Y, Nangia-Makker P, Tait L, Balan V, Hogan V, Pienta KJ, Raz A. 2009. Regulation of prostate cancer progression by Galectin-3. Am J Pathol. 174: 1515-1523.
88. Yin X, Rana K, Ponmudi V, King MR. 2010. Knockdown of fucosyltransferase iii disrupts the adhesion of circulating cancer cells to E-Selectin without affecting hematopoietic cell adhesion. Carbohydr Res. 345: 2334-2342.
89. Yu LG, Andrews N, Zhao Q, McKean D, Williams JF, Connor LJ, Gerasimenko OV, Hilkens J, Hirabayashi J, Kasai K, et al. 2007. Galectin-3 interaction with Thomsen-Friedenreich disaccharide on cancer-associated Muc1 causes increased cancer cell endothelial adhesion. J Biol Chem. 282: 773-781.
90. Zhao Q, Barclay M, Hilkens J, Guo X, Barrow H, Rhodes JM, Yu LG. 2010. Interaction between circulating Galectin-3 and cancer-associated Muc1 enhances tumour cell homotypic aggregation and prevents Anoikis. Mol Cancer. 9: 154.
91. Zhuo Y, Chammas R, Bellis SL. 2008. Sialylation of Beta1 integrins blocks cell adhesion to Galectin-3 and protects cells against Galectin-3-induced apoptosis. J Biol Chem. 283: 22177-22185.
92. Zick Y, Eisenstein M, Goren RA, Hadari YR, Levy Y, Ronen D. 2004. Role of Galectin-8 as a modulator of cell adhesion and cell growth. Glycoconj J. 19: 517-526.
93. Zou J, Glinsky VV, Landon LA, Matthews L, Deutscher SL. 2005. Peptides specific to the Galectin-3 carbohydrate recognition domain inhibit metastasis-associated cancer cell adhesion. Carcinogenesis. 26: 309-318.